Cardiovascular news.
SoRelle
R
R
D000083:Acetanilides; D000789:Angina, Unstable / Q000188:drug therapy / Q000517:prevention & control; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D000077425:Fondaparinux; D006801:Humans; D006827:Hydantoins; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D048289:Imidazolidines; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D020108:Nicorandil / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011134:Polysaccharides / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069458:Ranolazine; D016896:Treatment Outcome
D000083:Acetanilides; D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D005343:Fibrinolytic Agents; D006827:Hydantoins; D007093:Imidazoles; D048289:Imidazolidines; D010879:Piperazines; D011134:Polysaccharides; D020108:Nicorandil; C086123:azimilide; D000069458:Ranolazine; D000077425:Fondaparinux